Metastatic Renal Cell Carcinoma
Conditions
Keywords
Metastatic Renal Cell Carcinoma, First line, Eligible for sunitinib
Brief summary
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib. Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters.
Detailed description
This is a multicenter, open-label, randomized phase III study to investigate whether therapeutic vaccination with IMA901, a mult-peptide cancer vaccine (TUMAP), can prolong overall survival in patients with metastatic and/or locally advanced RCC when added to standard first-line therapy with sunitinib (primary endpoint). Secondary endpoints include a subgroup analysis of overall survival in patients who are positive for a prospectively defined primary biomarker signature (identified as being predictive for improved clinical outcome in IMA901-vaccinated patients in the previous phase II study), progression-free survival (PFS), best overall response, cellular immunomonitoring in a subset of patients, and safety. Safety analysis will be based on adverse events (AEs), physical examinations, vital signs, hematology, clinical chemistry, urinalysis and ECG changes. Further endpoints include subgroup analyses of overall survival in patients who are positive for further prospectively defined biomarkers (identified in the previous phase II study), and exploratory screening of new biomarkers (to be investigated in patients' blood and paraffin sections from tumor tissue) to predict better clinical outcome as response to vaccination with IMA901. Biomarker sets will not be used for patient selection in this study.
Interventions
DRUGSunitinib
As per label.
BIOLOGICALGM-CSF
Intradermal injection of GM-CSF as adjuvant.
DRUGCyclophosphamide
One single low-dose i.v. infusion prior to the first vaccination
DRUGIMA901
Intradermal vaccinations with IMA901 vaccine.
Sponsors
Immatics Biotechnologies GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged at least 18 years. 2. HLA type: HLA-A\*02-positive 3. Metastatic and/or locally advanced RCC with clear cell histology (histological confirmation by local pathologist required). NOTE: prior nephrectomy is NOT required. 4. Measurable and/or non-measurable tumor lesions as per RECIST 1.1 5. Patients who are candidates for a first-line therapy with sunitinib. 6. Favorable or intermediate risk according to the 6-score risk criteria in patients treated with VEGF-targeted agents according to Heng \[Heng et al. 2009\]. The patient has a favorable risk if none, or intermediate risk if one or two of the following criteria apply (if three or more criteria apply the patient is not eligible): 1. Hemoglobin \< LLN, 2. Serum corrected calcium \> ULN, 3. Karnofsky performance status \< 80%, 4. Time from initial diagnosis to initiation of therapy \< 1 year, 5. Absolute neutrophil count \> ULN, 6. Platelets \> ULN. 7. Able to understand the nature of the study and give written informed consent. 8. Willingness and ability to comply with the study protocol for the duration of the study. 9. Female patients who are post menopausal (no menstrual period for a minimum of 1 year), or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or practice a medically acceptable method of birth control. 10. Male patients willing to use contraception (upon study entry and during the course of the study or have undergone vasectomy.
Exclusion criteria
1. Prior systemic therapy for metastatic disease. (Note: prior adjuvant treatment for non-metastatic disease is allowed, however adjuvant therapy must have been stopped ≥ 1 year before Visit C). 2. History of or current brain metastases. 3. Abnormal ≥ CTC Grade 3 laboratory values for hematology (Hb, WBC, neutrophils, lymphocytes, platelets), liver (serum bilirubin, ALAT or ASAT) and renal function (serum creatinine). 4. Metastatic second malignancy. 5. Localized second malignancy expected to influence the patient's life span. 6. Patients with a history or evidence of systemic autoimmune disease, e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematodes (SLE), scleroderma, Sjögren's syndrome, Wegener's granulomatosis, Guillain-Barre syndrome. 7. Known active hepatitis B or C infection. 8. Known HIV infection. 9. Active infections requiring oral or intravenous antibiotics. 10. Any other known infection with a biological agent that can cause a severe disease and poses a severe danger to lab personnel working on patients' blood or tissue. 11. Received study drug within any clinical study (including approved and experimental drugs) within 4 weeks before sunitinib start. 12. Serious intercurrent illness, which according to the investigator, poses an undue risk for the patient when participating in the trial, including, but not limited to, any of the following: * Clinically significant cardiovascular disease (e.g., uncontrolled hypertension; clinically significant cardiac arrhythmia, clinically significant QT-prolongation), * New York Heart Association class III-IV congestive heart failure, * Symptomatic peripheral vascular disease, * Severe pulmonary dysfunction, * Psychiatric illness or social situation that would preclude study compliance. 13. Less than 12 months since any of the following: * Myocardial infarction, * Severe or unstable angina, * Coronary or peripheral artery bypass graft, * Cerebrovascular event incl. transient ischemic attack, * Pulmonary embolism / deep vein thrombosis (DVT). 14. Pregnancy or breastfeeding. 15. Any condition which in the judgment of the investigator would place the patient at undue risk or interfere with the results of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | 2015 (estimated) |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival in biomarker-defined subgroup | 2015 (estimated) |
| Progression-free survival | 2014 (estimated) |
| Best tumor response | 2014 (estimated) |
| Safety and tolerability | continuously |
| Cellular immunomonitoring | 2014 (estimated) |
Countries
France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, United Kingdom, United States
Outcome results
None listed